SRI teams up with ShangPharma to target Alzheimer’s

By Flora Southey

- Last updated on GMT

GettyImages/Boarding1Now
GettyImages/Boarding1Now

Related tags Clinical trial Pharmacology

ShangPharma Innovation and SRI International are collaborating to develop treatments for neurodegenerative and inflammatory conditions, such as Alzheimer’s disease.

Under the agreement, SRI will provide target specific mechanistic assays for screening, and ShangPharma Innovation (SPII) will provide in vivo ​models, to develop enzyme inhibitors that target brain inflammation.

“SPII is providing expert know-how in drug discovery and development and particularly in neurodegenerative disease ​[in vivo] models through its affiliate, ChemPartner,” ​said SRI spokesperson Dina Basin.

“We are also supplying Alzheimer’s disease expertise specific for this programme,” ​she added.

Unmet need

Basin said the partnership aims to respond to unmet need for Alzheimer’s disease treatments.

“SRI entered into the collaboration with SPII with the desire to expedite development of an effective drug to treat Alzheimer’s disease, which so far has no long term treatment options,” ​she told us.

Basin told us the California, US-based firms plan to license out the compounds.

Earlier this year​, Outsourcing-Pharma.com investigated the challenges facing Alzheimer’s research, with particular focus on the lack of volunteer participation in clinical trials.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers